KCND3
A-type voltage-gated potassium channel KCND3
As of the edition of 20 October 2026, KCND3 (A-type voltage-gated potassium channel KCND3, UniProt Q9UK17) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UK17
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 6
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Nervous system
- Registered trials of its drugs
- 18
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vernakalant | Marketed | Phase 4 | none listed |
| Ajmaline | Marketed | Phase 4 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Cipher Pharmaceuticals | Route B |
The other 2 companies at KCND3
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at KCND3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.